[go: up one dir, main page]

NI201300111A - Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa - Google Patents

Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa

Info

Publication number
NI201300111A
NI201300111A NI201300111A NI201300111A NI201300111A NI 201300111 A NI201300111 A NI 201300111A NI 201300111 A NI201300111 A NI 201300111A NI 201300111 A NI201300111 A NI 201300111A NI 201300111 A NI201300111 A NI 201300111A
Authority
NI
Nicaragua
Prior art keywords
acetyl
coa carboxylase
pyrazolospiroketone
derivatives
carboxylase inhibitors
Prior art date
Application number
NI201300111A
Other languages
English (en)
Inventor
Lee Dow Robert
Alfred Southers James Jr
James Edmonds David
Andrew Griffith David
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NI201300111A publication Critical patent/NI201300111A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Photographic Processing Devices Using Wet Methods (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona un compuesto de Fórmula (I) o una sal del mismo aceptable desde el punto de vista farmacéutico; donde G es fórmula II o fórmula III; R1, R2 y R3 son como se describe en la presente; composiciones farmacéuticas del mismo ; y el uso del mismo en el tratamiento de enfermedades, afecciones o trastornos modulados por la inhibición de una enzima(s) acetil - CoA carboxilasa en un animal.
NI201300111A 2011-04-22 2013-10-18 Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa NI201300111A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161478240P 2011-04-22 2011-04-22

Publications (1)

Publication Number Publication Date
NI201300111A true NI201300111A (es) 2014-02-12

Family

ID=46025823

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300111A NI201300111A (es) 2011-04-22 2013-10-18 Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa

Country Status (42)

Country Link
US (4) US8802688B2 (es)
EP (1) EP2699576B1 (es)
JP (1) JP5657174B2 (es)
KR (1) KR101567659B1 (es)
CN (2) CN106117205B (es)
AP (1) AP3499A (es)
AR (1) AR086198A1 (es)
AU (1) AU2012245996B2 (es)
CA (1) CA2831380C (es)
CL (1) CL2013002794A1 (es)
CO (1) CO6801757A2 (es)
CR (1) CR20130464A (es)
CU (1) CU24164B1 (es)
CY (1) CY1117122T1 (es)
DK (1) DK2699576T3 (es)
DO (1) DOP2013000243A (es)
EA (1) EA022375B1 (es)
EC (1) ECSP13013038A (es)
ES (1) ES2561452T3 (es)
GE (1) GEP20166474B (es)
GT (1) GT201300258A (es)
HR (1) HRP20151397T1 (es)
HU (1) HUE028602T2 (es)
IL (1) IL228949A (es)
MA (1) MA35061B1 (es)
ME (1) ME02312B (es)
MX (1) MX348860B (es)
MY (1) MY162167A (es)
NI (1) NI201300111A (es)
NZ (1) NZ616156A (es)
PE (1) PE20141187A1 (es)
PH (1) PH12013501941A1 (es)
PL (1) PL2699576T3 (es)
PT (1) PT2699576E (es)
RS (1) RS54526B1 (es)
SG (1) SG194142A1 (es)
SI (1) SI2699576T1 (es)
TN (1) TN2013000393A1 (es)
TW (1) TWI464171B (es)
UA (1) UA107753C2 (es)
UY (1) UY34027A (es)
WO (1) WO2012143813A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005429A (es) * 2009-11-10 2012-06-19 Pfizer Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa.
CN102491974B (zh) * 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-甲脒盐酸盐的合成方法
TWI630194B (zh) 2013-03-14 2018-07-21 凱立拉製藥公司 雙環止痛化合物
US10208063B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
US9988399B2 (en) 2013-05-10 2018-06-05 Gilead Apollo, Llc Bicyclic compounds as ACC inhibitors and uses thereof
JP6417403B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ, エルエルシー Acc阻害剤及びその使用
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
EP3670496A3 (en) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
JP6542794B2 (ja) * 2013-12-12 2019-07-10 ゼノ ロイアルティー アンド マイルストーンズ リミテッド ライアビリティー カンパニー 二環式アルキル化合物、および合成
EP3114107B1 (en) 2014-03-07 2020-07-22 Recurium IP Holdings, LLC Propellane derivates and synthesis
US10457502B2 (en) 2014-05-22 2019-10-29 Symbotic Canada Ulc Tool and method for layer depalletizing
KR20170048588A (ko) 2014-09-17 2017-05-08 카리라 파마슈티컬스, 아이앤씨. 바이사이클릭 화합물
WO2017114413A1 (zh) * 2015-12-31 2017-07-06 江苏天士力帝益药业有限公司 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
MX389668B (es) 2017-05-15 2025-03-20 Recurium Ip Holdings Llc Compuestos biciclo[1.1.1]pentilo sustituidos y uso de los mismos para el tratamiento del dolor y fiebre.
BR112020008413A2 (pt) 2017-11-21 2020-10-06 Pfizer Inc. sal 2-amino-2-(hidroximetil)propano-1,3-diol cristalino de ácido 4-(4-(1-isopropil-7-oxo-1,4,6, 7-tetra-hidroespiro[indazol-5,4?-piperidina]-1?-carbonil)-6-metoxipiridin-2-il)benzoico
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
CN118271307A (zh) * 2022-12-30 2024-07-02 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
WO2024213044A1 (en) * 2023-04-14 2024-10-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Azacyclo-carbonyl-fused ring derivatives and use thereof
WO2025036472A1 (en) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Spirocyclic mta-cooperative prmts inhibitor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
RS63203A (en) 2001-02-28 2006-12-15 Merck & Co.Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2003072197A1 (en) 2002-02-27 2003-09-04 Pfizer Products Inc. Acc inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (ja) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
PT1753748E (pt) 2004-05-12 2009-08-28 Pfizer Prod Inc Derivados de prolina e a sua utilização como inibidores de dipeptidil peptidase iv
WO2005113069A2 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2007011811A1 (en) 2005-07-19 2007-01-25 Merck & Co., Inc. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
WO2007013691A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited スピロ環化合物
CA2629406A1 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin aryl cgrp receptor antagonists
CA2641766A1 (en) 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP5190448B2 (ja) 2006-04-20 2013-04-24 ファイザー・プロダクツ・インク グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物
ATE552262T1 (de) 2006-11-29 2012-04-15 Pfizer Prod Inc Spiroketone als inhibitoren von acetyl-coa- carboxylase
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
US20100113418A1 (en) * 2007-02-20 2010-05-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP5404601B2 (ja) 2007-04-12 2014-02-05 ファイザー・インク 新規な3−アミド−ピロロ[3,4−c]ピラゾール−5(1H,4H,6H)カルバルデヒド誘導体
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
CA2724774C (en) 2008-05-28 2013-06-25 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
EP2297164A1 (en) 2008-05-28 2011-03-23 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
US8524730B2 (en) * 2008-07-04 2013-09-03 Msd K.K. Spirochromanone carboxylic acids
US8110570B2 (en) 2008-07-14 2012-02-07 Cropsolution, Inc. Modulators of acetyl-coenzyme A carboxylase and methods of use thereof
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
JP4825322B1 (ja) 2008-08-28 2011-11-30 ファイザー・インク ジオキサ−ビシクロ[3.2.1]オクタン−2,3,4−トリオール誘導体
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
AP3179A (en) 2009-03-11 2015-03-31 Pfizer Benzofuranyl derivatives used as glucokinase inhibitors
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
US20120095028A1 (en) 2009-03-20 2012-04-19 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
CA2759891A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
BRPI1014636A2 (pt) 2009-06-05 2016-04-05 Pfizer moduladores de gpr 119
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
EP2499140A1 (en) * 2009-11-10 2012-09-19 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
MX2012005429A (es) * 2009-11-10 2012-06-19 Pfizer Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa.
HUE031616T2 (hu) * 2010-09-30 2017-07-28 Pfizer N1-pirazol-spiroketon acetil-koenzim-A karboxiláz inhibítorok

Also Published As

Publication number Publication date
IL228949A (en) 2016-11-30
HRP20151397T1 (hr) 2016-01-15
AP3499A (en) 2015-12-31
US20120270893A1 (en) 2012-10-25
MX348860B (es) 2017-06-30
CN106117205B (zh) 2018-09-21
CU24164B1 (es) 2016-03-31
PE20141187A1 (es) 2014-09-18
TWI464171B (zh) 2014-12-11
JP5657174B2 (ja) 2015-01-21
DOP2013000243A (es) 2013-12-31
MY162167A (en) 2017-05-31
UA107753C2 (xx) 2015-02-10
CA2831380C (en) 2016-04-05
EA201391288A1 (ru) 2014-04-30
CN103492388A (zh) 2014-01-01
KR101567659B1 (ko) 2015-11-09
US8802688B2 (en) 2014-08-12
WO2012143813A1 (en) 2012-10-26
GEP20166474B (en) 2016-05-10
AU2012245996B2 (en) 2016-09-01
PL2699576T3 (pl) 2016-05-31
ME02312B (me) 2016-06-20
TN2013000393A1 (fr) 2015-01-20
NZ616156A (en) 2014-08-29
US20150112068A1 (en) 2015-04-23
RS54526B1 (en) 2016-06-30
SG194142A1 (en) 2013-11-29
CY1117122T1 (el) 2017-04-05
ECSP13013038A (es) 2014-01-31
AR086198A1 (es) 2013-11-27
EP2699576B1 (en) 2015-12-09
CR20130464A (es) 2013-10-16
PH12013501941A1 (en) 2021-06-23
EP2699576A1 (en) 2014-02-26
SI2699576T1 (sl) 2016-02-29
CO6801757A2 (es) 2013-11-29
UY34027A (es) 2013-04-05
AU2012245996A1 (en) 2013-10-03
US20140323730A1 (en) 2014-10-30
TW201305162A (zh) 2013-02-01
DK2699576T3 (en) 2016-02-15
ES2561452T3 (es) 2016-02-26
MA35061B1 (fr) 2014-04-03
HUE028602T2 (hu) 2016-12-28
CN106117205A (zh) 2016-11-16
CU20130126A7 (es) 2014-01-29
CA2831380A1 (en) 2012-10-26
US20150336958A1 (en) 2015-11-26
PT2699576E (pt) 2016-03-09
JP2014515755A (ja) 2014-07-03
CL2013002794A1 (es) 2013-12-27
MX2013012313A (es) 2014-01-31
AP2013007129A0 (en) 2013-09-30
EA022375B1 (ru) 2015-12-30
GT201300258A (es) 2015-06-02
IL228949A0 (en) 2013-12-31
KR20140015511A (ko) 2014-02-06

Similar Documents

Publication Publication Date Title
NI201300111A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
DOP2014000152A (es) Inhibidores de bromodominios
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
PH12016501461A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
EA201490754A1 (ru) Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
EA201692300A1 (ru) Производные карбоксамида
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
JO3192B1 (ar) مركب بنزوثيازولون
BR112020026507A8 (pt) Composto de isotiazolo[5,4-d]pirimidinas como inibidor de irak4
BR112016008704A8 (pt) derivados de indol-urea glucopiranosil-substituídos, composições farmacêuticas, e seus usos
DOP2014000116A (es) Inhibidores de la péptido desformilasa
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
CR20150391A (es) Derivados 2-((4-amino-3-(3-fluoro-5-hidroxifenilo)-1h-pirazolo[3,4-d]pirimidin-1-il)metilo)-3-(2-(trifluoro-metilo)bencilo)quinazolin-4(3h)-ona y su uso como inhibidores de quinasa-3 fosfoinositida
NZ621471A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof